Palvella Therapeutics Inc. (PVLA) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Palvella Therapeutics Inc. (NASDAQ: PVLA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $146.15 (-3.58% 1D, market cap $2.11B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PVLA ranks #361 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PVLA carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -27.9%. By comparison, LKFT (Lakefront Biotherapeutics) holds a D+ grade (57/100 RQD, P/E N/A, ROIC —, cap $2.13B) and IMNM (Immunome Inc.) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $2.15B). Among the 5-stock peer group, PVLA leads on earnings multiple (N/A) while SEPN leads on capital efficiency (-20.7% ROIC).
Per PVLA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001583648), Palvella Therapeutics Inc. generated $0 in revenue, -$41.7M in net income, and -$25.0M in free cash flow against $59.6M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±11.9% realized swing band)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While PVLA currently carries a cautious 45/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Big institutional funds and options desks are actively positioning on the bullish side.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($141.67) and Max Pain ($153.46) forces dealer call-delta covering toward $169.45.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Palvella Therapeutics Inc. (PVLA) dropped -3.58% to $146.15, trading at 83% of its 52-week range ($71.55 – $161.38). Stretched risk/reward at current multiples (-28% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance Australia report covering Palvella Therapeutics Inc. (PVLA) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Palvella Therapeutics Inc. (PVLA) market action, institutional positioning, and fundamental catalysts.
markets.businessinsider.com report covering Palvella Therapeutics Inc. (PVLA) market action, institutional positioning, and fundamental catalysts.
The Globe and Mail report covering Palvella Therapeutics Inc. (PVLA) market action, institutional positioning, and fundamental catalysts.
Investing.com Canada report covering Palvella Therapeutics Inc. (PVLA) market action, institutional positioning, and fundamental catalysts.
Mugglehead Investment Magazine report covering Palvella Therapeutics Inc. (PVLA) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Palvella Therapeutics Inc. (PVLA) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Palvella Therapeutics Inc. (PVLA) market action, institutional positioning, and fundamental catalysts.
QTORIN™ rapamycin could become the first FDA-approved therapy for microcystic lymphatic malformations, a serious, lifelong rare disease affecting an estimated more than 30,000 diagnosed children and adults in the U.S. Ph
Palvella Therapeutics (NASDAQ:PVLA) is preparing for a potential commercial launch of QTORIN rapamycin while advancing additional rare skin and vascular anomaly programs, Chief Financial Officer Matt Korenberg said durin
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on PVLA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for PVLA. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Palvella Therapeutics Inc. (PVLA) ranks #361 by composite RQD confidence (45/100, grade D) and #247 by equity capitalization ($2.11B). Within this direct 5-issuer industry benchmark cohort, PVLA leads on earnings valuation at N/A trailing P/E, while SEPN leads on capital efficiency and profitability with -20.7% ROIC and — gross margin. SEPN currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with PVLA at 45/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PVLA
ACTIVE
Palvella Therapeutics Inc. | D | 45/100 | — | — | -27.9% | -3.58% | $2.11B | Benchmark Subject |
| LKFT Lakefront Biotherapeutics | D+ | 57/100 | — | — | — | -0.15% | $2.13B | /lkft-vs-pvla → |
| IMNM Immunome Inc. | E | 26/100 | — | — | -35.0% | -0.44% | $2.15B | /imnm-vs-pvla → |
| SEPN Septerna Inc. | C | 63/100 | — | — | -20.7% | -2.72% | $2.05B | /sepn-vs-pvla → |
| SDGR Schrodinger Inc. | D+ | 53/100 | — | 55.7% | -35.0% | -9.50% | $2.03B | /sdgr-vs-pvla → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Palvella Therapeutics Inc. (PVLA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 , and -100.0% cumulative change since FY2023) , GAAP net income of -$41.7M, operating cash flow of -$25.0M, and free cash flow of -$25.0M (-130.7% YoY). On the balance sheet, PVLA closed FY2025 with $59.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$41.7M | -$25.0M | -$25.0M | $59.6M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$17.4M | -$10.8M | -$10.8M | $88.2M | — |
| FY2023 (FY) | 2023-12-31 | $42.8M | $18.7M | -$13.7M | -$13.7M | — | — |
As of 2026-11-03, Palvella Therapeutics Inc. (NASDAQ: PVLA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $146.15 (-3.58% 1D, market cap $2.11B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PVLA ranks #361 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PVLA carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -27.9%. By comparison, LKFT (Lakefront Biotherapeutics) holds a D+ grade (57/100 RQD, P/E N/A, ROIC —, cap $2.13B) and IMNM (Immunome Inc.) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $2.15B). Among the 5-stock peer group, PVLA leads on earnings multiple (N/A) while SEPN leads on capital efficiency (-20.7% ROIC).
Per PVLA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001583648), Palvella Therapeutics Inc. generated $0 in revenue, -$41.7M in net income, and -$25.0M in free cash flow against $59.6M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
PVLA last traded at $146.15 (-3.58% on volume of 293,067 shares), positioning the stock +3.16% above its 50-day simple moving average ($141.67) and +14.72% above its 200-day simple moving average ($127.40). Across its 52-week range of $71.55 to $161.38, PVLA sits at the 83.0% percentile with a 14-day RSI of 57.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±11.9% ($128.76 to $163.54).
Why PVLA Stock dropped -3.58% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-28% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, PVLA scores 47 out of 100, a letter grade of D, labeled "Roarable Sell — Underperform / Distribution Warning." Across the five pillars: Fundamental Cash Engine scores 7 of 20 (ROIC -27.9%; FCF yield -1.14%), indicating weak cash generation. Whale 13F Flow scores 17 of 20 (institutional accumulation and options positioning), the strongest pillar. Insider Conviction scores 3 of 20 (SEC Form 4 and Congressional PTR cluster flow), the weakest pillar. Macro Regime Fit scores 10 of 20 (Beta 1.0; sector sensitivity). Forensic Balance Sheet scores 10 of 20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5).
For a prospective investor evaluating the stock today, the pillar mix points to a divergence: institutional positioning is comparatively supportive, while cash-flow generation and insider signals are weak. Per the financials, the company reported no revenue in the FY 2025 and FY 2024 periods and negative free cash flow in each reported year, so the valuation case rests on factors outside current cash generation. The rating's verdict label signals distribution-related caution. Upside drivers are limited to the institutional flow and the catalyst headlines below; the principal tradeoff is that a $2.18B market capitalization is set against negative ROIC and negative FCF yield.
Palvella Therapeutics Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the profile, the company has a market capitalization of $2.2B. The source data does not describe its products, customers, or revenue model; the financials report $0.0M revenue for FY 2025 and FY 2024, and $42.8M for FY 2023.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-38.6M | $-41.7M | N/A | $-25.0M | $58.0M | N/A |
| FY 2024 | $0.0M | $-14.1M | $-17.4M | N/A | $-10.8M | $83.6M | N/A |
| FY 2023 | $42.8M | $-11.9M | $18.7M | N/A | $-13.7M | N/A | N/A |
Per the SEC financials, operating income and net income were negative in FY 2025 and FY 2024, and FCF was negative in all three reported periods. Per the market data, gross, operating, and net margins are each 0%, and ROIC is -27.9%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 2/9, and Debt/Equity is 0.5. Cash declined from $83.6M in FY 2024 to $58.0M in FY 2025.
Real-time company headlines, analyst actions, and sector developments for Palvella Therapeutics Inc. (PVLA) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance Australia report covering Palvella Therapeutics Inc. (PVLA) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Palvella Therapeutics Inc. (PVLA) market action, institutional positioning, and fundamental catalysts.
markets.businessinsider.com report covering Palvella Therapeutics Inc. (PVLA) market action, institutional positioning, and fundamental catalysts.
The Globe and Mail report covering Palvella Therapeutics Inc. (PVLA) market action, institutional positioning, and fundamental catalysts.
Investing.com Canada report covering Palvella Therapeutics Inc. (PVLA) market action, institutional positioning, and fundamental catalysts.
Mugglehead Investment Magazine report covering Palvella Therapeutics Inc. (PVLA) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Palvella Therapeutics Inc. (PVLA) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Palvella Therapeutics Inc. (PVLA) market action, institutional positioning, and fundamental catalysts.
Welcome to the PVLA (Palvella Therapeutics Inc.) Roar Pit. Current RQD Composite is 47/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on PVLA, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Palvella Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on PVLA, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $151.58 (52-wk range $71.55 - $161.38), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).